VisionGate Presents Clinical Data At IASLC Meeting Showing Its Cell-CT™ 3D Imaging Platform Detects Lung Cancer With High Sensitivity And Specificity

SYDNEY and PHOENIX, Oct. 28, 2013 — VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT™, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer.Continue reading